Global Neurodiagnostics and Portable Ultrasound Markets Forecast Strong Growth

The neurodiagnostics market, valued at US$19.35 billion in 2025, is projected to reach US$27.2 billion by 2034, expanding at a 3.85% CAGR. Growth is driven by an increasing prevalence of neurological disorders such as Alzheimer’s and Parkinson’s, rapid advances in imaging technologies—including high‑resolution MRI, PET and AI‑enhanced brain imaging platforms launched by Philips and SyntheticMR in March 2024—and an ageing global population. Restraints include high equipment costs and a shortage of skilled professionals, while opportunities lie in biomarker research and tele‑medicine integration.

The portable ultrasound market is expected to rise from US$2.49 billion in 2025 to US$3.84 billion by 2030, a 9.0% CAGR. Expansion is fueled by the adoption of point‑of‑care ultrasound (POCUS) across emergency, rural and home‑care settings, the growing burden of chronic diseases, and technological advancements such as device miniaturisation, AI‑assisted imaging and wireless connectivity. Leading firms—including GE Healthcare, Philips Healthcare and Siemens Healthineers—are broadening their handheld product portfolios to support diverse clinical applications and tele‑medicine workflows.